← Research library

Potential of peptidergic nootropic therapy in developmental dysphasia in children

Randomized study in people · 2019

What was studied
54 children aged 3–4 with developmental dysphasia
Main finding
Randomized comparison with no drug treatment reported speech and parent-questionnaire changes over two months.

Active vocabulary · 2.3-fold increase with Cortexin versus 1.4-fold without medication

Reported findings and study design

Open randomized comparison of 54 children aged 3–4 with developmental dysphasia: 27 received one 10-day intramuscular course, and 27 received no drug. All parents received speech-stimulation guidance. Outcomes were assessed at day 60.

Population or model 54 children aged 3–4 with developmental dysphasia

Dose, route and schedule

One 10-day course of daily intramuscular Cortexin. The article specifies 0.5 mg/kg for children under 20 kg and 10 mg for children over 20 kg. This describes the historical study.

Protocol source ↗ · Original Russian journal methods

Results · Original 2019 full text and Table 1
MeasureResultComparison, timing and statistics
Active vocabulary2.3-fold increase with Cortexin versus 1.4-fold without medication
Spoken phrases3.6-fold increase with Cortexin versus 1.5-fold without medication
Adverse eventsThe authors reported none during treatment in this small study
Selected language measures from Table 1
Selected language measures from Table 1
MeasureDayCortexin (n = 27)No medication (n = 27)
Active vocabulary, words013.7 ± 1.815.4 ± 1.5
Active vocabulary, words6031.7 ± 5.622.0 ± 2.0
Spoken phrases02.0 ± 0.42.1 ± 0.4
Spoken phrases607.1 ± 1.13.1 ± 0.5

Mean ± standard error as reported. Both groups improved in words and phrases on within-group testing.

The fold changes compare each arm with its own baseline. The open design, lack of placebo, and caregiver-reported measures limit causal inference. Matching arm sizes and selected outcomes suggest overlap with the 2020 report.

Source for these results ↗ · Reviewed 2026-11-10

Study limitations and source details

Study limitations

  • No masking described; parental ratings and speech-development advice are relevant co-interventions.
  • Pediatric clinical findings do not establish enhancement or safety in healthy adults.

Source details

Original Russian article, methods and selected outcome tables checked.

Sources checked

Citation

Randomized trialFull text available

Zavadenko NN, Davydova LA, Suvorinova NY, Khondkaryan GS. Potential of peptidergic nootropic therapy in developmental dysphasia in children Zh Nevrol Psikhiatr Im S S Korsakova 119(11):47-53. PMID 31851172

Study source ↗ · DOI 10.17116/jnevro201911911147 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards